Healthcare Industry News:  Hematide 

Biopharmaceuticals Personnel

 News Release - June 4, 2008

Affymax(R) Announces Executive Management Promotions

PALO ALTO, Calif.--(HSMN NewsFeed)--Affymax, Inc. (Nasdaq:AFFY ) today announced the promotions of Robert F. Venteicher, Ph.D. to senior vice president, Technical Operations and Grace U. Shin, J.D., to general counsel.

“I am pleased to recognize the significant and important contributions that both Bob and Grace have made in the growth and maturity of our business,” said Arlene M. Morris, president and chief executive officer of Affymax. “Importantly, each has assumed critical leadership roles in the advancement of our Phase 3 product, Hematide™. Bob has been instrumental in leading the clinical manufacture of the product, preparing for eventual commercial supply and working closely with our partner, Takeda Pharmaceutical on the Joint Steering Committee. Grace has expanded her role in legal affairs for Affymax, including leading contract agreement efforts with hundreds of clinical trial sites that are participating in the Hematide Phase 3 program in the United States and Europe. In addition, Grace was instrumental in our successful transition to a public company and has led the institution of the necessary policies and procedures for SEC reporting and compliance.”

Dr. Venteicher joined Affymax in August 2007 as vice president, Technical Operations with nearly 30 years of experience in pharmaceutical and biotechnology drug development. Dr. Venteicher is experienced in managing supply chain and quality strategies for contracted and collaborative business alliances for development and commercial products sourced globally. Dr. Venteicher joined Affymax from Elan Pharmaceuticals, Inc., where he held a number of positions, including vice president, R&D Quality and Compliance. Prior to that, he served as vice president, Quality Assurance/Quality Control at Univax Biologics, Inc. Earlier in his career, he held the positions of head, R&D Pharmaceutical Quality Control and associate director of Bioprocess and Analytical Development at Centocor Inc. He also held scientific and management positions with increasing responsibilities during his 10-year tenure at Hoffmann LaRoche, Inc.

Ms. Shin joined Affymax as vice president, legal affairs and corporate counsel. Prior to joining Affymax, she was vice president of legal affairs and corporate counsel for FibroGen, a biotechnology company. Prior to her position at FibroGen, she was a corporate attorney at Pacific Gas & Electric Company in San Francisco, focusing on debt and equity financings and intellectual property matters. She began her law career as a business associate at Cooley Godward in San Francisco.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax’s lead product candidate, Hematide™, is currently in Phase 3 clinical trial stage for the treatment of anemia associated with chronic renal failure and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company’s clinical trials and drug development program. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.


Source: Affymax

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.